AR063153A1 - Anticuerpo monoclonal para prevenir/tratar el cancer - Google Patents

Anticuerpo monoclonal para prevenir/tratar el cancer

Info

Publication number
AR063153A1
AR063153A1 ARP070104425A ARP070104425A AR063153A1 AR 063153 A1 AR063153 A1 AR 063153A1 AR P070104425 A ARP070104425 A AR P070104425A AR P070104425 A ARP070104425 A AR P070104425A AR 063153 A1 AR063153 A1 AR 063153A1
Authority
AR
Argentina
Prior art keywords
nectin
prevent
monoclonal antibody
treat cancer
cancer
Prior art date
Application number
ARP070104425A
Other languages
English (en)
Inventor
Sato Shuji
Oshima Tsutomu
Kurokawa Tomofumi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44083820&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR063153(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/JP2006/320429 external-priority patent/WO2007043635A1/ja
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR063153A1 publication Critical patent/AR063153A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Un anticuerpo monoclonal humano contra una proteína que comprende la misma o sustancialmente la misma secuencia de aminoácidos que la secuencia de aminoácidos representada por la SEC ID N°:1 o SEC ID N°: 3, su péptido parcial o una sal del mismo, es util como agente para prevenir/tratar el cáncer. Un inductor de apoptosis de células cancerosas, un inhibidor del crecimiento de células cancerosas, un agente citotoxico contra células cancerosas a través de un mecanismo de defensa del huésped mediado por la region FC de un anticuerpo y demás. Reivindicacion 9: El anticuerpo de acuerdo con la reivindicacion 1, caracterizado porque tiene actividad inhibitoria de la union trans de nectina-2/nectina-3 o nectina-2/nectina-2. Reivindicacion 15: Una célula de hibridoma, caracterizado porque es capaz de producir el anticuerpo de acuerdo con la reivindicacion 1.
ARP070104425A 2006-10-06 2007-10-09 Anticuerpo monoclonal para prevenir/tratar el cancer AR063153A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/JP2006/320429 WO2007043635A1 (ja) 2005-10-07 2006-10-06 癌の予防・治療剤
CL200700974A CL2007000974A1 (es) 2005-10-07 2007-04-05 Anticuerpo monoclonal anti-nectina 2; composicion farmaceutica que lo comprende; y su uso para tratar o prevenir el cancer.
JP2007100876 2007-04-06

Publications (1)

Publication Number Publication Date
AR063153A1 true AR063153A1 (es) 2008-12-30

Family

ID=44083820

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104425A AR063153A1 (es) 2006-10-06 2007-10-09 Anticuerpo monoclonal para prevenir/tratar el cancer

Country Status (21)

Country Link
US (1) US20100008928A1 (es)
EP (1) EP2067791A4 (es)
JP (1) JPWO2008044754A1 (es)
KR (1) KR20090078339A (es)
CN (1) CN101541834A (es)
AR (1) AR063153A1 (es)
AU (1) AU2007307536A1 (es)
BR (1) BRPI0717024A2 (es)
CA (1) CA2666249A1 (es)
CL (1) CL2007002879A1 (es)
CO (1) CO6190538A2 (es)
EC (1) ECSP099276A (es)
IL (1) IL197389A0 (es)
MA (1) MA30816B1 (es)
MX (1) MX2009003126A (es)
NO (1) NO20091783L (es)
PE (1) PE20081456A1 (es)
RU (1) RU2009117237A (es)
TN (1) TN2009000090A1 (es)
TW (1) TW200823235A (es)
WO (1) WO2008044754A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011352205B2 (en) * 2010-12-31 2016-06-16 Bioatla, Llc Express humanization of antibodies
WO2013018891A1 (ja) * 2011-08-04 2013-02-07 東レ株式会社 癌の治療及び／又は予防用医薬組成物
US20140056890A1 (en) * 2012-06-06 2014-02-27 Oncomed Pharmaceuticals, Inc. Binding Agents That Modulate the Hippo Pathway and Uses Thereof
WO2014069681A1 (ko) * 2012-10-29 2014-05-08 인제대학교 산학협력단 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
WO2014069682A1 (ko) * 2012-10-29 2014-05-08 인제대학교 산학협력단 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
EP3978929A1 (en) 2015-02-19 2022-04-06 Compugen Ltd. Pvrig polypeptides and methods of treatment
EP3295951B1 (en) 2015-02-19 2020-04-22 Compugen Ltd. Anti-pvrig antibodies and methods of use
JO3620B1 (ar) * 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
DK3347379T5 (da) 2016-08-17 2020-06-15 Compugen Ltd Anti-tigit-antistoffer, anti-pvrig-antistoffer og kombinationer deraf
MX2019006072A (es) 2016-11-30 2019-08-14 Oncomed Pharm Inc Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit).
WO2018220446A1 (en) 2017-06-01 2018-12-06 Compugen Ltd. Triple combination antibody therapies
CA3106114A1 (en) 2018-07-20 2020-01-23 Surface Oncology, Inc. Anti-cd112r compositions and methods
JP2024503508A (ja) 2021-01-15 2024-01-25 シージェン インコーポレイテッド 免疫調節性抗体－薬物コンジュゲート
EP4288109A1 (en) 2021-02-03 2023-12-13 Seagen Inc. Immunostimulatory compounds and conjugates
WO2023161943A1 (en) * 2022-02-28 2023-08-31 Nectin Therapeutics Ltd. Humanized antibodies against nectin-2 and drug conjugates thereof
WO2023215740A1 (en) 2022-05-06 2023-11-09 Seagen Inc. Immunomodulatory antibody-drug conjugates
WO2024030577A1 (en) 2022-08-03 2024-02-08 Seagen Inc. Immunostimulatory anti-pd-l1-drug conjugates
EP4321522A1 (en) 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
WO1999063063A1 (en) 1998-06-03 1999-12-09 Northwestern University Cellular proteins which mediate herpesvirus entry
US20030129685A1 (en) * 1998-10-28 2003-07-10 Jian Ni 12 human secreted proteins
DE19852800C1 (de) 1998-11-16 2000-04-13 Univ Albert Ludwigs Freiburg Verfahren zur Herstellung von Antikörpern gegen ein Polypeptid, von dem die kodierende Nukleinsäure bekannt ist
US20030022279A1 (en) * 1999-06-14 2003-01-30 Fraser Christopher C. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
AU2001266787A1 (en) 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2002213053B2 (en) 2000-10-05 2006-12-21 Immunex Corporation Nectin polypeptides, polynucleotides, methods of making and use thereof
EP1402058A4 (en) 2001-06-05 2006-02-01 Exelixis Inc DGKS AS P53 PATH MODIFICATORS AND METHOD OF USE
CA2449303C (en) 2001-06-06 2014-10-14 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
WO2003020743A1 (en) 2001-09-05 2003-03-13 Regeneron Pharmaceuticals, Inc. Methods of expressing transgenes
KR20040101502A (ko) * 2002-04-16 2004-12-02 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
US20070224201A1 (en) 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20080260742A1 (en) * 2004-04-09 2008-10-23 Takeda Pharmaceutical Company Limited Preventives/Remedies for Cancer

Also Published As

Publication number Publication date
MX2009003126A (es) 2009-04-06
CA2666249A1 (en) 2008-04-17
AU2007307536A1 (en) 2008-04-17
NO20091783L (no) 2009-07-01
PE20081456A1 (es) 2008-11-27
AU2007307536A2 (en) 2009-04-30
JPWO2008044754A1 (ja) 2010-02-18
WO2008044754A1 (fr) 2008-04-17
MA30816B1 (fr) 2009-10-01
CL2007002879A1 (es) 2008-06-27
EP2067791A4 (en) 2009-11-25
US20100008928A1 (en) 2010-01-14
TW200823235A (en) 2008-06-01
EP2067791A1 (en) 2009-06-10
ECSP099276A (es) 2009-06-30
BRPI0717024A2 (pt) 2014-03-11
IL197389A0 (en) 2011-08-01
CN101541834A (zh) 2009-09-23
RU2009117237A (ru) 2010-11-20
TN2009000090A1 (en) 2010-08-19
KR20090078339A (ko) 2009-07-17
CO6190538A2 (es) 2010-08-19

Similar Documents

Publication Publication Date Title
AR063153A1 (es) Anticuerpo monoclonal para prevenir/tratar el cancer
ES2675375T3 (es) Anticuerpos monoclonales contra claudina 18 para el tratamiento del cáncer
CO6450656A2 (es) Anticuerpos anti-tnf-alfa y sus usos
MX2011006685A (es) Inhibidores de metaloproteinas de matriz de membrana tipo-1 y sus usos.
PH12014501083A1 (en) Anticancer fusion protein
AR066338A1 (es) Proteinas toxinas activas contra hemipteros y coleopteros de bacillus thuringiensis
MX349513B (es) Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
EA201390820A1 (ru) Слитый белок против рака
MX339203B (es) Proteina de fusion anticancer.
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
EP4306123A3 (en) Saposin-a derived peptides and uses thereof
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
EA201391546A1 (ru) Противораковый слитый белок
AR060362A1 (es) Agente para prevenir / tratar el cancer
MX2022014231A (es) Conjugados de anticuerpo-farmaco que se enfocan a la uparap.
MX2016002556A (es) Métodos y composiciones para el tratamiento de patologías del tejido de cartílago y disco.
CR10676A (es) Agente para prevenir/ tratar el cancer
CL2009000811A1 (es) Polipeptido con actividad antimicrobiana que comprende una secuencia aminoacidica de al menos un 90% de identidad con la secuencia id no:1 para producir un medicamento para tratar la meningitis; uso de dicho polipeptido para tratar la meningitis.
PH12014502198B1 (en) Osteoprotegerin derived composition and use thereof
PL415392A1 (pl) Sekwencja białkowa, zwłaszcza  fragment przeciwciała, stanowiący inhibitor VEGF-C oraz jej zastosowanie
WO2022099034A3 (en) Mitochondrial protein targeting engineered deubiquitinases and methods of use thereof
MX2022005461A (es) Plantas deficientes en rop que tienen una alta eficiencia en el uso del agua.
Medvedev et al. Construction of the Coding Sequence of the Transcription Variant 2 of the Human Renalase Gene and Its Expression in the Prokaryotic System
DOP2009000065A (es) Agente para prevenir/tratar el cancer
TH150144A (th) แอนติ-dr5 แอนติบอดีชนิดใหม่

Legal Events

Date Code Title Description
FB Suspension of granting procedure